Login to Your Account

Ampio seeking nod for osteoarthritis, despite failed Ampion 'PIVOT'al trial

By Michael Fitzhugh
Staff Writer

Thursday, June 30, 2016

Ampio Pharmaceuticals Inc. missed the primary endpoint in its second pivotal trial for Ampion, a candidate for treating osteoarthritis of the of the knee, tested under an FDA SPA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription